Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARgamma responsive models of type 2 diabetes is described.
Henry
James R
JR
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. jrhenry@lilly.com
Li
Yihong
Y
Warshawsky
Alan M
AM
Brozinick
Joseph T
JT
Hawkins
Eric D
ED
Misener
Elizabeth A
EA
Briere
Daniel A
DA
Montrose-Rafizadeh
Chahrzad
C
Zink
Richard W
RW
Yumibe
Nathan P
NP
Ajamie
Rose T
RT
Wilken
Brad
B
Devanarayan
Viswanath
V
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D051379:Mice; D008958:Models, Molecular; D047495:PPAR gamma / Q000819:agonists* / Q000187:drug effects; D047492:Peroxisome Proliferator-Activated Receptors / Q000037:antagonists & inhibitors; D000077154:Rosiglitazone; D044005:Tetrahydroisoquinolines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D045162:Thiazolidinediones / Q000494:pharmacology
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors; D044005:Tetrahydroisoquinolines; D045162:Thiazolidinediones; D000077154:Rosiglitazone